Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) | PAR 22 185

Opportunity Information: Apply for PAR 22 185

The Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed) is a National Institutes of Health (NIH) funding opportunity designed to help researchers move promising HIV therapeutics closer to the clinic by providing access to targeted, "gap-filling" preclinical services. Rather than primarily serving as a traditional research grant to fund an entire project from start to finish, this program is structured as a way for investigators to request specific preclinical development support that they may not have in-house, may be too expensive to obtain independently, or may be a bottleneck preventing further advancement of a candidate therapy. The overall aim is to speed the development pipeline for new therapeutics addressing HIV and key HIV-associated co-infections, specifically Hepatitis B, Hepatitis C, and Tuberculosis.

A central feature of this opportunity is its emphasis on practical product-development needs in the preclinical stage. The program is geared toward helping academic groups and private sector teams overcome missing pieces that stand between a promising concept or lead compound and the next stage of development. In plain terms, it supports the kind of enabling work that often determines whether a therapeutic candidate can credibly progress toward human testing, such as specialized studies, assays, or other preclinical services intended to strengthen a development package. Even though the award mechanism is listed as a grant, the FOA language highlights services-oriented support to facilitate product advancement, and it explicitly states that clinical trials are not allowed under this opportunity.

The opportunity is listed as discretionary funding and uses a grant funding instrument, with a health-related activity category and CFDA number 93.855. The Funding Opportunity Number is PAR 22 185, and it was created on May 27, 2022. The original closing date provided is January 17, 2025. The notice does not specify an award ceiling or the expected number of awards in the provided source data, which usually means applicants should rely on the full FOA text and any related NIH guide notices for details on scope, available resources, review considerations, and any limits tied to the particular services requested.

Eligibility is broad and inclusive, reflecting the program's intent to support a wide range of institutions and organizations involved in HIV and co-infection therapeutic development. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; and Native American tribal organizations other than federally recognized tribal governments. Nonprofit organizations are eligible whether or not they hold 501(c)(3) status, and both for-profit organizations (other than small businesses) and small businesses may apply. Public housing authorities/Indian housing authorities are also included, along with an "others" category that is further expanded by the FOA to explicitly name additional eligible groups.

The FOA also calls out several categories of institutions and organizations as eligible, underscoring an effort to broaden participation and ensure access across diverse communities and regions. These include Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; and even non-domestic (non-U.S.) entities, meaning foreign organizations may apply. It also notes eligibility for Indian/Native American tribal governments other than federally recognized ones, which can be important for certain community-based or tribally affiliated research and development efforts.

Taken together, RAPIDD is best understood as an NIH pathway for researchers who already have a therapeutic concept or candidate with promise in HIV or HIV-related co-infections, but who need specific preclinical development help to de-risk the candidate and build a stronger case for the next stages of translation. The program targets the kinds of preclinical gaps that can stall progress and offers a structured way to obtain the services needed to push viable therapeutics forward, while keeping the work firmly on the preclinical side (no clinical trials).

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Resources Access for Preclinical Integrated Drug Development (RAPIDD) Program (X01 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855.
• This funding opportunity was created on 2022-05-27.
• Applicants must submit their applications by 2025-01-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 22 185

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: